US Patent 8,158,645: Topotecan Monohydrochloride Pentahydrate, Formulation Scope, and Patent Landscape

US Patent 8,158,645 protects a narrow combination of three elements: topotecan monohydrochloride pentahydrate, a defined powder X-ray diffraction profile, and dispersion in glyceryl monostearate plus hydrogenated vegetable oil. Claims 2 through 10 add specific recrystallization conditions. Claims 11 and 12 cover a separate high-organic-solvent slurry process.

The patent does not broadly cover topotecan, topotecan hydrochloride generally, conventional topotecan injection, or every topotecan hydrate. A potentially infringing product would need to satisfy the claimed solid-state, formulation, and, for process-dependent claims, manufacturing limitations.

What does US Patent 8,158,645 protect?

The patent has two independent composition claims:

Claim	Independent?	Core subject matter
1	Yes	Topotecan monohydrochloride pentahydrate with an XRPD pattern substantially the same as Figure 1, dispersed in glyceryl monostearate and hydrogenated vegetable oil
2	No	Claim 1 composition, with pentahydrate prepared using acetone or tetrahydrofuran and an organic-to-aqueous solvent ratio of about 1.5:1 to 3:1
11	Yes	Claim 1 composition, with pentahydrate prepared by slurrying in an aqueous organic mineral-acid mixture at an organic-to-aqueous ratio of about 8:1
12	No	Claim 11 composition using 0.05 N aqueous hydrochloric acid

The patent therefore has two principal claim groups:

A solid-form and excipient combination in claim 1.
The same composition tied to specified crystallization or slurry processes in claims 2 through 12.

The formulation limitation is central. The claims require dispersion of topotecan monohydrochloride in both glyceryl monostearate and hydrogenated vegetable oil. A formulation using only one of those excipients would not literally satisfy the claim.

How should claim 1 be construed?

Claim 1 requires the following elements:

A pharmaceutical composition.
Topotecan monohydrochloride.
The topotecan must be a pentahydrate product.
The product must have an XRPD pattern substantially the same as Figure 1.
The topotecan must be dispersed in a mixture of glyceryl monostearate and hydrogenated vegetable oil.
The composition must be prepared by that dispersion process.

The claim is narrower than a conventional chemical compound claim. It does not claim the molecular structure of topotecan monohydrochloride in all forms. It claims a particular solid form combined with a particular excipient system.

The phrase “substantially the same as FIG. 1” creates a technical comparison issue. The relevant inquiry would ordinarily involve the peak positions, relative intensities, peak breadth, and permitted analytical variation. A competing manufacturer could challenge infringement by showing that its material is a different hydrate, polymorph, amorphous form, or crystalline form with materially different diffraction characteristics.

A product-by-process limitation may create additional claim-construction issues. Federal Circuit precedent generally distinguishes between process language used to define a product and process steps that limit infringement. The result depends on the claim language, prosecution history, and whether the claimed product can be distinguished from products made by other processes. See In re Thorpe, 777 F.2d 695 (Fed. Cir. 1985); Abbott Laboratories v. Sandoz, Inc., 566 F.3d 1282 (Fed. Cir. 2009).

What do claims 2 through 10 add?

Claims 2 through 10 narrow claim 1 by specifying the preparation of the pentahydrate.

Claims 2 through 5: acetone or tetrahydrofuran recrystallization

Claim 2 requires:

An aqueous organic solvent mixture containing topotecan monohydrochloride.
Acetone or tetrahydrofuran as the organic solvent.
An organic-to-aqueous solvent ratio of about 1.5:1 to about 3:1.
Recrystallization to precipitate the pentahydrate.
Filtration to collect the product.

Claim 3 limits the aqueous phase to an aqueous mineral acid solution, specifically 0.05 N hydrochloric acid.

Claim 4 requires acetone and 0.05 N aqueous hydrochloric acid.

Claim 5 narrows the ratio to approximately 2:1 acetone to aqueous hydrochloric acid.

These claims are process-specific. A manufacturer using ethanol, methanol, water alone, a different acid concentration, or a materially different solvent ratio may avoid literal infringement of these dependent claims while still facing claim 1 if the resulting product and excipient system meet claim 1.

Claims 6 through 10: heated crystallization and controlled cooling

Claim 6 adds:

Initial dissolution in a heated aqueous organic solvent mixture.
Crystallization or recrystallization by cooling.
Filtration.
Drying.

Claim 7 specifies:

Acetone and 0.05 N aqueous hydrochloric acid.
Heating to about 58°C.
An acetone-to-aqueous-acid ratio of approximately 2:1.

Claim 8 requires a cooling rate of about 0.1°C/min to about 1°C/min.

Claim 9 narrows that rate to approximately 0.25°C/min.

Claim 10 requires cooling to a range extending from room temperature to approximately 0°C.

Claims 7 through 10 are vulnerable to noninfringement based on process deviations. The practical issue is whether the process limitations are legally treated as limitations on the claimed composition or merely as descriptive manufacturing language. That question would turn on the patent’s specification, prosecution history, and the accused product’s identity.

What do claims 11 and 12 cover?

Claims 11 and 12 represent a separate process route.

Claim 11 requires:

An aqueous organic solvent mixture.
An aqueous mineral acid solution.
Acetone or tetrahydrofuran as the organic solvent.
An organic-to-aqueous solvent ratio of approximately 8:1.
Slurrying topotecan monohydrochloride in that mixture.
Formation of the pentahydrate.
Filtration.
Dispersion of the resulting pentahydrate in glyceryl monostearate and hydrogenated vegetable oil.

Claim 12 specifies 0.05 N aqueous hydrochloric acid.

The 8:1 ratio materially distinguishes claim 11 from claims 2 through 10, which principally address ratios of 1.5:1 to 3:1. A process using the 8:1 slurry route could fall within claim 11 even if it does not use the heated 58°C crystallization process in claim 7.

What formulations are protected by US 8,158,645?

The patent’s formulation coverage is defined by the excipient combination rather than by a dosage strength or route of administration.

Covered formulation characteristics

A formulation is within the apparent scope of claim 1 if it contains:

Topotecan monohydrochloride pentahydrate;
the claimed Figure 1 XRPD form;
glyceryl monostearate; and
hydrogenated vegetable oil;

with the topotecan dispersed in the mixture.

The claims do not state:

A minimum or maximum topotecan concentration.
A required ratio between glyceryl monostearate and hydrogenated vegetable oil.
A required dosage form.
A required particle size.
A required route of administration.
A required release profile.
A required packaging configuration.
A required stability period.

That absence gives claim 1 potentially broad coverage within the specified excipient and solid-form combination. It also creates validity and construction questions because the claim may reach multiple physical formulations that have materially different pharmaceutical performance.

Formulations apparently outside the literal claim language

The following would generally fall outside claim 1 unless additional facts establish equivalent structure or process:

Topotecan hydrochloride solution without either claimed lipid excipient.
Topotecan in glyceryl monostearate alone.
Topotecan in hydrogenated vegetable oil alone.
Topotecan free base.
An amorphous topotecan hydrochloride form.
A different hydrate or polymorph with a materially different XRPD pattern.
A composition using another lipid matrix, such as glyceryl behenate or a nonhydrogenated vegetable oil.
A product in which topotecan is not dispersed in the claimed excipient mixture.

The doctrine of equivalents could expand the practical risk, but courts usually assess equivalence limitation by limitation. Substantial differences in crystal form or excipient identity may be difficult to overcome, particularly where the patent emphasizes those features as the invention.

How strong is the patent estate based on the supplied claims?

The claim set has moderate technical specificity and a mixed enforcement profile.

Strength factor	Assessment
Solid-form definition	Potentially strong if Figure 1 provides reproducible, distinctive XRPD characteristics
Excipient limitation	Strong against products using the same two excipients; easy to design around with another matrix
Process limitations	Potentially difficult to prove without manufacturing discovery
Claim 1 breadth	Broader than claims 2 through 12 because it omits detailed crystallization conditions
Claim differentiation	Claims 2 through 12 provide several narrower fallback positions
Dependence on analytical testing	High; XRPD and hydrate characterization would be central
Design-around potential	Material, particularly through different excipients, solid forms, or process conditions
Generic product risk	Product-specific rather than category-wide

The independent claims do not protect all topotecan products. Their value depends on whether a commercial competitor needs the claimed pentahydrate and lipid dispersion to achieve the targeted product profile.

When does US Patent 8,158,645 lose exclusivity?

A precise expiration date cannot be determined from the claims supplied. Patent term is generally measured from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory rules. See 35 U.S.C. §§ 154 and 156.

The patent issued in 2012, but the issue date alone does not establish the expiration date. A patent issued on April 17, 2012, for example, could expire materially earlier or later than April 17, 2032, depending on its earliest priority and nonprovisional filing dates.

The relevant exclusivity analysis requires separation of:

Patent expiration.
FDA drug-substance or drug-product exclusivity.
Any pediatric exclusivity.
Any patent-term extension.
Any terminal disclaimer.
The presence or absence of Orange Book listing.

Patent expiration also does not automatically authorize generic launch where other unexpired patents, regulatory exclusivities, injunctions, or settlement restrictions apply.

What is the Orange Book status of US Patent 8,158,645?

The supplied claims do not establish whether US 8,158,645 was listed in the FDA Orange Book for a specific topotecan reference product.

Orange Book listing generally depends on whether the patent claims the drug substance, drug product, or an approved method of use, and whether the NDA holder submitted the patent for listing under FDA requirements. A formulation patent that does not correspond to an approved product may not create a Paragraph IV certification obligation for every abbreviated new drug application.

For a topotecan generic, the relevant questions would include:

Whether the patent is listed against Hycamtin or another approved topotecan NDA.
Whether the listed claims cover the generic’s formulation.
Whether the ANDA applicant uses the claimed pentahydrate.
Whether the applicant certifies Paragraph IV, III, or no certification.
Whether the NDA holder brought a Hatch-Waxman action within 45 days.
Whether a 30-month stay was triggered.

The patent claims alone do not establish any of those regulatory facts. FDA Orange Book records and ANDA litigation filings control the analysis. [1]

Which companies may challenge or design around the patent?

Potential challengers would include manufacturers of:

Topotecan hydrochloride injection.
Topotecan capsules.
Alternative oral solid formulations.
Lipid-based topotecan delivery systems.
Contract manufacturers producing topotecan pentahydrate.
Suppliers of the active pharmaceutical ingredient.

The highest-risk competitor would be one using the same pentahydrate XRPD form in a formulation containing both glyceryl monostearate and hydrogenated vegetable oil. A conventional injectable generic using an aqueous solution would present a different infringement profile because the asserted claims require dispersion in the specified lipid mixture.

A generic applicant could pursue several design-around strategies:

Use a different hydrate or polymorph.
Use amorphous topotecan hydrochloride.
Replace one or both claimed excipients.
Use a different organic solvent system.
Use a different organic-to-aqueous ratio.
Avoid the claimed slurry or controlled-cooling process.
Demonstrate that the final product does not have the Figure 1 XRPD pattern.

The first three strategies are generally more commercially meaningful than process changes because process changes may still produce the same claimed solid form.

What Paragraph IV risks exist?

A Paragraph IV challenge would typically argue that the listed patent is invalid, unenforceable, or not infringed. The principal potential grounds suggested by the claim structure are:

Anticipation and obviousness

A challenger could examine earlier disclosures of:

Topotecan hydrochloride hydrates.
XRPD-defined crystalline forms.
Recrystallization from acetone and aqueous hydrochloric acid.
Lipid dispersions containing glyceryl monostearate.
Hydrogenated vegetable oil formulations.
Combining a known hydrate with known pharmaceutical excipients.

The patent’s vulnerability would depend on whether the prior art disclosed the same combination, not merely its individual components. Obviousness could focus on whether a skilled formulator would have had a reasonable expectation of obtaining the claimed pentahydrate and using it in the claimed lipid matrix. See 35 U.S.C. § 103.

Indefiniteness

The phrase “substantially the same as FIG. 1” could be challenged if the patent does not provide objective boundaries for determining conformity. The risk increases if the specification lacks peak tables, measurement conditions, acceptable variation, and methods for distinguishing the claimed product from related hydrates.

Written description and enablement

A challenger could argue that the claims cover a broader range of excipient amounts, physical forms, or manufacturing conditions than the specification supports. Claims 1 and 11 are especially relevant because they use broad formulation language while incorporating a specific crystal-form requirement.

Product-by-process enforcement

Claims 2 through 12 could generate disputes over whether an accused product made by another process infringes if it is otherwise the same pentahydrate composition. The prosecution history would be important.

What patent litigation and settlement issues affect the analysis?

The supplied claim text does not identify any infringement complaint, ANDA filing, settlement agreement, license, consent judgment, or injunction involving US 8,158,645.

For commercial diligence, the relevant litigation records would include:

Federal district court Hatch-Waxman complaints.
Paragraph IV notice letters.
Patent Trial and Appeal Board petitions.
Claim-construction orders.
Infringement and invalidity opinions.
Settlement terms governing launch dates.
License agreements covering topotecan solid forms or formulations.
Covenants not to sue.
Terminal-disclaimer or ownership records.

A settlement can materially change launch timing even when a patent remains unexpired. Conversely, the absence of a reported case does not establish that a patent is commercially irrelevant.

Does biosimilar risk apply to topotecan?

No. Topotecan is a small-molecule drug, not a biologic. The relevant competitive pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under section 351(k) of the Public Health Service Act.

The main regulatory risks are therefore:

Orange Book patent listing.
Paragraph IV certification.
Bioequivalence.
Formulation differences.
Pharmaceutical-equivalence requirements.
Manufacturing consistency for the claimed hydrate.
Patent litigation and settlement restrictions.

How does this patent compare with broad topotecan patents?

US 8,158,645 is narrower than a basic compound patent and narrower than a broad method-of-treatment patent.

Patent category	Typical scope	Relationship to US 8,158,645
Compound patent	Topotecan or a broad chemical genus	Much broader chemically
Salt patent	Topotecan hydrochloride	Broader than the pentahydrate limitation
Solid-form patent	Specific hydrate or polymorph	Closely related
Formulation patent	Topotecan plus excipients or delivery system	Directly relevant
Method-of-use patent	Treating a disease with topotecan	Separate infringement theory
Manufacturing patent	Producing topotecan or an intermediate	Relevant to API suppliers
US 8,158,645	Pentahydrate XRPD form plus two-excipient dispersion and specified preparation routes	Narrow combination patent

A competitor may avoid this patent while still needing to assess other patents covering the active ingredient, manufacturing process, dosage form, method of treatment, or approved product.

What is the geographic coverage?

The patent provides rights only in the United States. Corresponding foreign applications, granted patents, national-phase filings, and expiration dates must be assessed separately.

The highest-value jurisdictions for a topotecan formulation estate would normally include:

United States.
European Patent Convention states.
Japan.
China.
Canada.
Australia.
South Korea.
India.

A US noninfringement or invalidity result does not determine the outcome of corresponding foreign rights. Claim scope, prosecution history, patent term, supplementary protection rights, and litigation status vary by jurisdiction.

Key Takeaways

US 8,158,645 is a combination patent covering topotecan monohydrochloride pentahydrate, a Figure 1 XRPD profile, and dispersion in glyceryl monostearate plus hydrogenated vegetable oil.
Claim 1 is the broadest claim and does not require the detailed crystallization conditions found in claims 2 through 12.
Claims 2 through 10 focus on acetone or tetrahydrofuran recrystallization, including a 2:1 acetone-to-acid ratio, 58°C heating, and controlled cooling.
Claims 11 and 12 cover a distinct approximately 8:1 organic-to-aqueous slurry process using aqueous mineral acid.
Conventional topotecan injection and formulations lacking the two specified lipid excipients do not appear to fall within the literal scope of the supplied claims.
The central technical enforcement issues are XRPD identity, hydrate state, excipient composition, and the legal effect of product-by-process language.
Topotecan has generic, not biosimilar, competition.
Orange Book listing, current patent term, Paragraph IV activity, litigation, licenses, and settlements cannot be established from the claim text alone.

FAQs

Does US 8,158,645 cover topotecan hydrochloride injection?

The supplied claims do not broadly cover aqueous topotecan hydrochloride injection. They require dispersion in glyceryl monostearate and hydrogenated vegetable oil.

Can a generic avoid the patent by using a different topotecan hydrate?

Potentially. A materially different hydrate or polymorph that does not have an XRPD pattern substantially the same as Figure 1 could avoid the solid-form limitation, subject to equivalents and other patent rights.

Is the 2:1 acetone-to-hydrochloric-acid ratio required for every claim?

No. The ratio is required by claim 5 and incorporated into certain dependent claims. Claim 1 does not recite that ratio.

Does the patent claim glyceryl monostearate by itself?

No. The claims require glyceryl monostearate in a mixture with hydrogenated vegetable oil.

What testing would be central in an infringement dispute?

The principal testing would likely include XRPD, hydrate and water-content analysis, excipient identification and quantification, process-record discovery, and comparison of the accused product with the patent’s Figure 1 pattern.

References

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
United States Congress. (2024). 35 U.S.C. § 103: Conditions for patentability; non-obvious subject matter.
United States Congress. (2024). 35 U.S.C. § 154: Contents and term of patent; provisional rights.
United States Congress. (2024). 35 U.S.C. § 156: Extension of patent term.
United States Patent and Trademark Office. (2012). U.S. Patent No. 8,158,645.
Abbott Laboratories v. Sandoz, Inc., 566 F.3d 1282 (Fed. Cir. 2009).
In re Thorpe, 777 F.2d 695 (Fed. Cir. 1985).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	046579	⤷ Start Trial
Australia	2004289318	⤷ Start Trial
Brazil	PI0416366	⤷ Start Trial
Canada	2545876	⤷ Start Trial
China	1913897	⤷ Start Trial
European Patent Office	1689400	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,158,645

Summary for Patent: 8,158,645